Advanced EGFR-mutant patients with strong PD-L1 expressions, defined as Tumor Proportion Score (TPS) ≧50%, have a greater chance of showing de novo resistance to EGFR-TKIs than patients with PD-L1 < 50%22,23. The gene discussed is EGFR; the disease is neoplasm.